GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » E10

PDL BioPharma (PDL BioPharma) E10 : $0.85 (As of Jun. 2020)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

PDL BioPharma's adjusted earnings per share data for the three months ended in Jun. 2020 was $-0.430. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.85 for the trailing ten years ended in Jun. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-26), PDL BioPharma's current stock price is $2.47. PDL BioPharma's E10 for the quarter that ended in Jun. 2020 was $0.85. PDL BioPharma's Shiller PE Ratio of today is 2.91.


PDL BioPharma E10 Historical Data

The historical data trend for PDL BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma E10 Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 1.08 1.20 1.14 0.97

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.03 0.97 0.93 0.85

Competitive Comparison of PDL BioPharma's E10

For the Biotechnology subindustry, PDL BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDL BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's Shiller PE Ratio falls into.



PDL BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PDL BioPharma's adjusted earnings per share data for the three months ended in Jun. 2020 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=-0.43/108.7673*108.7673
=-0.430

Current CPI (Jun. 2020) = 108.7673.

PDL BioPharma Quarterly Data

per share eps CPI Adj_EPS
201009 0.240 92.162 0.283
201012 -0.220 92.474 -0.259
201103 0.250 94.283 0.288
201106 0.380 95.235 0.434
201109 0.280 95.727 0.318
201112 0.270 95.213 0.308
201203 0.290 96.783 0.326
201206 0.520 96.819 0.584
201209 0.320 97.633 0.356
201212 0.340 96.871 0.382
201303 0.360 98.209 0.399
201306 0.620 98.518 0.685
201309 0.360 98.790 0.396
201312 0.350 98.326 0.387
201403 0.440 99.695 0.480
201406 0.520 100.560 0.562
201409 0.610 100.428 0.661
201412 0.320 99.070 0.351
201503 0.500 99.621 0.546
201506 0.470 100.684 0.508
201509 0.420 100.392 0.455
201512 0.610 99.792 0.665
201603 0.340 100.470 0.368
201606 0.030 101.688 0.032
201609 0.080 101.861 0.085
201612 -0.060 101.863 -0.064
201703 0.040 102.862 0.042
201706 0.390 103.349 0.410
201709 0.140 104.136 0.146
201712 0.150 104.011 0.157
201803 0.010 105.290 0.010
201806 -0.760 106.317 -0.778
201809 0.180 106.507 0.184
201812 0.110 105.998 0.113
201903 0.050 107.251 0.051
201906 -0.040 108.070 -0.040
201909 -0.160 108.329 -0.161
201912 -0.480 108.420 -0.482
202003 -0.260 108.902 -0.260
202006 -0.430 108.767 -0.430

Add all the adjusted EPS together and divide 10 will get our e10.


PDL BioPharma  (NAS:PDLI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PDL BioPharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2.47/0.85
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


PDL BioPharma E10 Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010